Daily GLP-1 Pill Shows Promise for Weight Loss

Here’s a breakdown of teh information ⁤provided​ in the text:

Research Article:

*⁤ ‍ Title: ‍ Orforglipron, an ​oral ⁤small-molecule GLP-1 receptor agonist, for ⁣the treatment of⁢ obesity⁢ in peopel with type 2 diabetes (ATTAIN-2)
* Journal: The Lancet

* Authors: Deborah B Horn et al.
* Study​ Type: Phase 3, double-blind, ⁣randomised, multicentre, placebo-controlled​ trial
* DOI: 10.1016/s0140-6736(25)02165-8
* ‍ publication Year: ‌ 2025

Source of Information:

* Provided by: University of‌ Texas ‌Health Science Center at Houston
* Website: http://www.uthouston.edu/

News Article/Release Information:

*​ topic: Daily oral GLP-1 ⁣pill a promising alternative to injectables for weight loss.
* Date: November 23, ‍2025
*​ Citation: Daily ⁤oral GLP-1 pill a promising ⁣alternative to injectables for weight loss, clinical⁣ trial finds⁤ (2025, November ​23)

In essence, this text describes a⁣ new research study published in The Lancet about an oral medication (orforglipron)​ for obesity adn type 2 diabetes, ⁣and it⁤ notes that the information is‌ being shared by the University of Texas Health Science Center‌ at Houston.